Ravulizumab
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
Product Specifications
CAS Number
1803171-55-2
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Complement System
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
